Platelet aggregation inhibitors: Difference between revisions
Jump to navigation
Jump to search
imported>Robert Badgett No edit summary |
imported>Robert Badgett |
||
| Line 13: | Line 13: | ||
===Thienopyridines=== | ===Thienopyridines=== | ||
[[Thienopyridines]] include [[clopidogrel]] and [[ | [[Thienopyridines]] include [[clopidogrel]], [[ticlopidine]], and the prodrug [[prasugrel]]. | ||
==References== | ==References== | ||
<references/> | <references/> | ||
Revision as of 21:53, 21 October 2009
Platelet aggregation inhibitors, also called antiplatelet drugs, are "drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system."[1]
Classification
Adenosine diphosphate (ADP) blocker
This includes dipyrimadole.
Cyclooxygenase-1 blockers
Cyclooxygenase-1 blockers include aspirin.
Glycoprotein IIb/IIIa inhibitors
Inhibitors of the platelet glycoprotein GPIIb-IIIa complex include eptifibatide, tirofiban, and the monoclonal antibody abciximab.
Thienopyridines
Thienopyridines include clopidogrel, ticlopidine, and the prodrug prasugrel.
References
- ↑ Anonymous (2024), Platelet aggregation inhibitors (English). Medical Subject Headings. U.S. National Library of Medicine.